420 results on '"Daling, JR"'
Search Results
2. Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis.
- Author
-
Chow EJ, Kamineni A, Daling JR, Fraser A, Wiggins CL, Mineau GP, Hamre MR, Severson RK, Drews-Botsch C, and Mueller BA
- Published
- 2009
- Full Text
- View/download PDF
Catalog
3. Timing of menarche and first full-term birth in relation to breast cancer risk.
- Author
-
Li CI, Malone KE, Daling JR, Potter JD, Bernstein L, Marchbanks PA, Strom BL, Simon MS, Press MF, Ursin G, Burkman RT, Folger SG, Norman S, McDonald JA, and Spirtas R
- Abstract
Ages at menarche and first birth are established risk factors for breast cancer. The interval between these ages may also affect risk, since the breast is more susceptible to carcinogenic insults during this period than during the parous period. However, few investigators have studied this relation. Using logistic regression, the authors evaluated associations between the timing of reproductive events and breast cancer risk among 4,013 cases and 4,069 controls enrolled in a multicenter, population-based US case-control study of White and African-American women (1994-1998). For White, parous premenopausal and postmenopausal women, those who had an interval of > or =16 years between the ages of menarche and first birth had 1.5-fold (95% confidence interval (CI): 1.0, 2.2) and 1.4-fold (95% CI: 1.1, 1.8) increased risks of breast cancer, respectively, in comparison with those who had < or =5 years between these ages. Adjusting for age at first birth altered these risk estimates somewhat, to odds ratios of 1.5 (95% CI: 0.8, 2.9) and 1.0 (95% CI: 0.6, 1.5), respectively. These associations were stronger for lobular and hormone-receptor-positive tumors but were absent among premenopausal African-American women. The authors conclude that the interval between age at menarche and age at first birth is associated with the risk of hormonally sensitive types of breast cancer, particularly among White women. [ABSTRACT FROM AUTHOR] more...
- Published
- 2008
4. Risk of functional ovarian cyst: effects of smoking and marijuana use according to body mass index.
- Author
-
Holt VL, Cushing-Haugen KL, and Daling JR
- Abstract
Smoking is one of the few risk factors that have been identified for functional ovarian cysts, and results of one epidemiologic study suggest that body mass index (BMI; weight (kg)/height (m)(2)) may modify the effect of this exposure. The current study assessed the association of cigarette smoking and marijuana use with functional ovarian cyst risk by using data from a population-based 1990-1995 case-control study of 586 incident functional ovarian cyst cases and 757 age-matched controls in a large health maintenance organization in Washington State. In multivariate analyses controlling for age, education, and reference year, the authors found an increase in risk associated with current cigarette smoking among women whose BMI was <20 (odds ratio (OR) = 2.48, 95% confidence interval (CI): 1.32, 4.64) or 20-25 (OR = 1.60, 95% CI: 1.04, 2.46) but not >25 (OR = 0.85, 95% CI: 0.53, 1.37). Corresponding risks associated with current marijuana use were BMI <20, OR = 2.05 (95% CI: 0.89, 4.75); BMI 20-25, OR = 1.78 (95% CI: 1.00, 3.17); and BMI >25, OR = 0.72 (95% CI: 0.36, 1.42). Study results indicate that increased BMI may attenuate the adverse effect of smoking on the risk of functional ovarian cyst. [ABSTRACT FROM AUTHOR] more...
- Published
- 2005
5. Body mass index, weight, and oral contraceptive failure risk.
- Author
-
Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, and Daling JR
- Published
- 2005
- Full Text
- View/download PDF
6. Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas.
- Author
-
Reed SD, Cushing-Haugen KKL, Daling JR, Scholes D, Schwartz SM, Reed, Susan D, Cushing-Haugen, Kara L, Daling, Janet R, Scholes, Delia, and Schwartz, Stephen M
- Published
- 2004
- Full Text
- View/download PDF
7. Oral contraceptives, tubal sterilization, and functional ovarian cyst risk.
- Author
-
Holt VL, Cushing-Haugen KL, Daling JR, Holt, Victoria L, Cushing-Haugen, Kara L, and Daling, Janet R
- Published
- 2003
- Full Text
- View/download PDF
8. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
- Author
-
Li CI, Malone KE, Porter PL, Weiss NS, Tang MC, Cushing-Haugen KL, Daling JR, Li, Christopher I, Malone, Kathleen E, Porter, Peggy L, Weiss, Noel S, Tang, Mei-Tzu C, Cushing-Haugen, Kara L, and Daling, Janet R more...
- Abstract
Context: Women using combined estrogen and progestin hormone replacement therapy (CHRT) have an increased risk of breast cancer; however, data on use for long durations and on risk associated with patterns of use are lacking.Objective: To evaluate relationships between durations and patterns of CHRT use and risk of breast cancer by histological type and hormone receptor status.Design: Population-based case-control study.Setting: Three counties in western Washington State.Participants: Nine hundred seventy-five women 65-79 years of age diagnosed with invasive breast cancer from April 1, 1997, through May 31, 1999 (histology: 196 lobular cases, 656 ductal cases, 114 cases with other histological type, and 9 cases with an unspecified histological type; estrogen receptor (ER)/progesterone receptor (PR) status: 646 ER+/PR+ cases, 147 ER+/PR- cases, and 101 ER-/PR- cases [6 ER-/PR+ cases and 75 cases with unknown ER/PR status were not included in the analyses herein]) and 1007 population controls.Main Outcome Measures: Risks of invasive lobular, ductal, ER+/PR+, ER+/PR-, and ER-/PR- breast carcinomas.Results: Women using unopposed estrogen replacement therapy (ERT) (exclusive ERT use), even for 25 years or longer, had no appreciable increase in risk of breast cancer, although the associated odds ratios were not inconsistent with a possible small effect. Ever users of CHRT (includes CHRT users who also had used ERT) had a 1.7-fold (95% confidence interval [CI], 1.3-2.2) increased risk of breast cancer, including a 2.7-fold (95% CI, 1.7-4.3) increased risk of invasive lobular carcinoma, a 1.5-fold (95% CI, 1.1-2.0) increased risk of invasive ductal carcinoma, and a 2.0-fold (95% CI, 1.5-2.7) increased risk of ER+/PR+ breast cancers. The increase in risk was greatest in those using CHRT for longer durations (users for 5-14.9 years and >or=15 years had 1.5-fold [95% CI, 1.0-2.3] and 1.6-fold [95% CI, 1.0-2.6] increases in risk of invasive ductal carcinoma, respectively, and 3.7-fold [95% CI, 2.0-6.6] and 2.6-fold [95% CI, 1.3-5.3] increases in risk of invasive lobular carcinoma, respectively. Associations of similar magnitudes were seen among users of both sequential and continuous CHRT. Risks of ER+/PR- and ER-/PR- tumors were not increased by use of any form of hormone replacement therapy; however, small numbers of these tumors limited power to detect possible associations.Conclusion: These data suggest that use of CHRT is associated with an increased risk of breast cancer, particularly invasive lobular tumors, whether the progestin component was taken in a sequential or in a continuous manner. [ABSTRACT FROM AUTHOR] more...- Published
- 2003
9. Trends in incidence rates of invasive lobular and ductal breast carcinoma.
- Author
-
Li CI, Anderson BO, Daling JR, Moe RE, Li, Christopher I, Anderson, Benjamin O, Daling, Janet R, and Moe, Roger E
- Abstract
Context: Research has suggested that use of combined estrogen and progestin hormone replacement therapy (CHRT) increases breast cancer risk and that CHRT use is more strongly associated with the risk of invasive lobular breast carcinoma than that of invasive ductal carcinoma. Lobular carcinoma is less common than ductal carcinoma but can be more difficult to diagnose because of its subtle elusive infiltrative pattern.Objective: To evaluate trends in invasive lobular and ductal carcinoma incidence rates from 1987 through 1999, during which time use of CHRT increased in the United States.Design: Descriptive epidemiologic study.Setting: Nine cancer registries that participate in the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute and that cover Atlanta, Ga; Detroit, Mich; San Francisco-Oakland, Calif; Seattle, Wash; and Connecticut, Hawaii, Iowa, New Mexico, and Utah.Population: Women 30 years of age and older residing in the areas covered by the 9 SEER registries.Main Outcome Measures: Proportional changes in incidence rates of invasive lobular and ductal carcinoma among women with no prior history of breast cancer.Results: A total of 190 458 women were included in this analysis who were identified through the registries as having invasive breast cancer; 7682 of the 198 140 potentially eligible women (ie, those identified as not having in situ breast cancer) were excluded from this analysis because stage of cancer was unknown. Invasive breast cancer incidence rates adjusted for age and for SEER historic stage increased 1.04-fold (95% confidence interval [CI], 1.004-1.07) from 1987-1999 (206.7/100 000 to 214.1/100 000, age-adjusted). However, incidence rates of tumors classified as lobular increased 1.52-fold (95% CI, 1.42-1.63), and those classified as mixed ductal-lobular increased 1.96-fold (95% CI, 1.80-2.14); rates of these types combined increased 1.65-fold (95% CI, 1.55-1.78) (19.8/100 000 to 33.4/100 000, age-adjusted). In contrast, ductal carcinoma rates remained largely constant (153.8/100 000 to 155.3/100 000, age-adjusted; proportional change, 1.03 [95% CI, 0.99-1.06]). The proportion of breast cancers with a lobular component increased from 9.5% in 1987 to 15.6% in 1999.Conclusions: Ductal carcinoma incidence rates remained essentially constant from 1987-1999 while lobular carcinoma rates increased steadily. This increase presents a clinical challenge given that lobular carcinoma is more difficult to detect than ductal carcinoma by both physical examination and mammography. [ABSTRACT FROM AUTHOR] more...- Published
- 2003
10. Hormone replacement therapy regimens and breast cancer risk(1).
- Author
-
Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Berlin JA, Weber AL, Doody DR, Wingo PA, McDonald JA, Malone KE, Folger SG, Spirtas R, and Weiss, Linda K more...
- Published
- 2002
- Full Text
- View/download PDF
11. Maternal and infant outcomes after injury during pregnancy in Washington State from 1989 to 1997.
- Author
-
Schiff MA, Holt VL, and Daling JR
- Published
- 2002
- Full Text
- View/download PDF
12. Body weight and risk of oral contraceptive failure.
- Author
-
Holt VL, Cushing-Haugen KL, Daling JR, Holt, Victoria L, Cushing-Haugen, Kara L, and Daling, Janet R
- Published
- 2002
- Full Text
- View/download PDF
13. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer.
- Author
-
Li CI, Malone KE, Weiss NS, Daling JR, Li, C I, Malone, K E, Weiss, N S, and Daling, J R
- Abstract
Background: Women diagnosed with breast cancer have a twofold to sixfold greater risk of developing contralateral breast cancer than women in the general population have of developing a first breast cancer. Tamoxifen therapy reduces this risk, but it is unclear if this benefit exists for both estrogen receptor (ER)-positive and ER-negative contralateral tumors.Methods: Using data from a population-based tumor registry that collects information on the ER status of breast tumors, we followed 8981 women residing in western Washington State who were diagnosed with a primary unilateral invasive breast cancer during the period from 1990 through 1998 to identify cases of contralateral breast cancer. We restricted our analyses to women who were at least 50 years old and whose first breast cancer had a localized or regional stage; women who received adjuvant hormonal therapy but not chemotherapy (n = 4654) were classified as tamoxifen users, while those who received neither adjuvant hormonal therapy nor chemotherapy (n = 4327) were classified as nonusers of tamoxifen. By reviewing selected patient abstracts, we estimated that 94% of the subjects were classified correctly with respect to tamoxifen use. The risk of contralateral breast cancer associated with tamoxifen use was estimated with the use of Cox regression. All statistical tests were two-sided.Results: Of the 89 tamoxifen users and 100 nonusers of tamoxifen diagnosed with contralateral breast cancer, 112 had ER-positive tumors, 20 had ER-negative tumors, and 57 had tumors with an ER status that was unknown or had not been determined by an immunohistochemical assay. The risk of developing an ER-positive and an ER-negative contralateral tumor among tamoxifen users was 0.8 (95% confidence interval [CI] = 0.5 to 1.1) and 4.9 (95% CI = 1.4 to 17.4), respectively, times that of nonusers of tamoxifen. This difference in risk by ER status was statistically significant (P<.0001).Conclusions: Tamoxifen use appears to decrease the risk of ER-positive contralateral breast tumors, but it appears to increase the risk of ER-negative contralateral tumors. [ABSTRACT FROM AUTHOR] more...- Published
- 2001
- Full Text
- View/download PDF
14. Anthropometric variables in relation to risk of breast cancer in middle-aged women.
- Author
-
Li, CI, Stanford, JL, Daling, JR, Li, C I, Stanford, J L, and Daling, J R
- Abstract
Background: Many epidemiological studies have assessed the relationships between anthropometric variables and breast cancer risk. However, methodological approaches for analysing these factors differ appreciably. Also, age when maximum height is achieved has been identified as a potential risk factor for breast cancer in premenopausal women, but this issue has not been studied in postmenopausal women.Methods: The participants in this population-based case-control study were postmenopausal women 50-64 years of age from the general female population of western Washington State. It included 479 women with incident primary breast cancer and 435 controls.Results: This study found that: (i) women who gained over 70 pounds since age 18 had an increased risk of breast cancer relative to those who stayed within 10 pounds of their weight at age 18 (odds ratio [OR] = 2.7; 95% CI: 1.5-4.9), (ii) women with body mass indices (BMI) below what is considered healthy had a decreased risk (OR = 0.4; 95% CI: 0.2-1.1) while women with a BMI in the obese range had an increased risk of breast cancer (OR = 1.4; 95% CI: 1.0-2.1), and (iii) women who reached their maximum height at or after the age of 18 had a decreased risk of breast cancer compared to women who reached their maximum height at age 13 or younger (OR = 0.7; 95% CI: 0.5-1.0).Conclusions: By examining various anthropometric variables using clinically relevant strata, a clearer picture of how these variables relate to postmenopausal breast cancer risk was developed. Similar to younger women, postmenopausal women who reached their maximum height at later ages had a decreased risk of breast cancer. [ABSTRACT FROM AUTHOR] more...- Published
- 2000
- Full Text
- View/download PDF
15. Comparison of self-report data and medical records data: results from a case-control study on prostate cancer.
- Author
-
Zhu, K, McKnight, B, Stergachis, A, Daling, JR, Levine, RS, Daling, J R, and Levine, R S
- Abstract
Background: Self-report and review of medical records are the most common methods for the assessment of past exposures. However, information obtained from self-reports and medical records may not be consistent. This study compared information provided in a self-administered questionnaire with medical records data.Methods: Self-report and medical records data came from a case-control study on prostate cancer. Cases were 181 patients with primary prostate cancer and controls were 297 men without the disease, enrolled in Group Health Cooperative (GHC) in Seattle. The consistencies between the two data sources were examined.Results: In general, agreement between the two data sources was almost perfect for demographic and anthropometric variables, substantial for the history of inguinal hernia and kidney stones, and moderate for vasectomy, family history of prostate cancer, smoking and alcohol consumption. However, the two data sources generally were poorly concordant for prior genitourinary diseases that have less explicit diagnostic criteria such as benign prostatic hyperplasia and prostatitis. Analyses of discordant data showed that men were more likely to report an exposure or medical condition that could not be verified from medical records. No discernible patterns in the difference of agreement were found according to age, GHC membership length or case-control status.Conclusions: This study suggests that agreement between self-reported data and medical records data varies depending upon the study variables. While both data sources are subject to some problems, self-report may provide more complete and comparable information, at least for variables unrelated to diagnosis. [ABSTRACT FROM AUTHOR] more...- Published
- 1999
- Full Text
- View/download PDF
16. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.
- Author
-
Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA, Malone, K E, Daling, J R, Thompson, J D, O'Brien, C A, Francisco, L V, and Ostrander, E A
- Abstract
Context: Studies of high-risk families with multiple early-onset cases of breast cancer have been useful for assessing the type and spectrum of germline mutations on the BRCA1 gene, but do not provide guidance to women with modest family history profiles. Thus, studies of women from the general population are needed to determine the BRCA1 mutation frequency in women perceived to be at high risk, and to develop profiles of those most likely to be carriers.Objective: To characterize frequency and spectrum of germline BRCA1 mutations in 2 categories of women identified via population-based studies hypothesized to be at increased risk of carrying such mutations: those diagnosed as having breast cancer before age 35 years and those diagnosed before age 45 years who have first-degree breast cancer family history.Design: Study subjects were drawn from 2 population-based case-control studies of breast cancer in young women on the basis of their family history or their age of diagnosis. Cases were younger than 35 years or were younger than 45 years with first-degree family history at the time of breast cancer diagnosis and were ascertained via a population-based cancer registry, and controls (women without breast cancer) were identified via random-digit dialing.Setting: Three counties in western Washington State.Main Outcome Measure: BRCA1 germline mutations in study subjects identified in DNA from peripheral blood lymphocytes by single-strand conformation polymorphism analysis using primer pairs that span the BRCA1 coding region and intron-exon boundaries.Results: Of 193 women diagnosed as having breast cancer before age 35 years, none of whom were selected on the basis of family history status, 12 (6.2%, 95% confidence interval [CI], 3.2%-10.6%) had germline BRCA1 mutations. In 208 women diagnosed before age 45 years who had first-degree breast cancer family history, 15 (7.2%, 95% CI,4.1%-11.6%) had germline mutations in BRCA1. In both groups, there were variations in mutation frequency noted by age and by family history. Mutation frequency decreased with increasing age of diagnosis. Higher proportions of mutations were seen in cases with at least 1 relative diagnosed as having breast cancer before age 45 years, in cases with greater numbers of affected relatives, and those with ovarian cancer family history. Mutation frequency did not vary by bilateral breast cancer family history. No frameshift or nonsense mutations were observed in 71 control women with a first-degree family history, although missense changes of unknown significance were seen in cases and controls.Conclusions: Women with BRCA1 germline mutations lacked a common family history profile. Also, a large proportion of the women with a first-degree breast cancer family history and women diagnosed as having breast cancer before age 35 years did not carry germline BRCA1 mutations. Hence, while early-onset disease and a strong breast cancer family history may be useful guidelines for checking BRCA1 status, these findings on women drawn from the general population suggest that it may be difficult to develop BRCA1 mutation screening criteria among women with modest family history profiles. [ABSTRACT FROM AUTHOR] more...- Published
- 1998
- Full Text
- View/download PDF
17. History of lactation and breast cancer risk.
- Author
-
Yang CP, Weiss NS, Band PR, Gallagher RP, White E, and Daling JR
- Published
- 1993
- Full Text
- View/download PDF
18. Maternal cigarette smoking and the risk of tubal pregnancy.
- Author
-
Stergachis A, Scholes D, Daling JR, Weiss NS, and Chu J
- Published
- 1991
- Full Text
- View/download PDF
19. Risk factors for incident and recurrent condylomata acuminata among women. A population-based study.
- Author
-
Habel LA, Van Den Eeden SK, Sherman KJ, McKnight B, Stergachis A, Daling JR, Habel, L A, Van Den Eeden, S K, Sherman, K J, McKnight, B, Stergachis, A, and Daling, J R
- Published
- 1998
- Full Text
- View/download PDF
20. Risk factors for incident and recurrent condylomata acuminata among men. A population-based study.
- Author
-
Van Den Eeden SK, Habel LA, Sherman KJ, McKnight B, Stergachis A, Daling JR, Van Den Eeden, S K, Habel, L A, Sherman, K J, McKnight, B, Stergachis, A, and Daling, J R
- Published
- 1998
- Full Text
- View/download PDF
21. Seroprevalence of and risk factors for antibodies to herpes simplex viruses, hepatitis B, and hepatitis C among southwestern Hispanic and non-Hispanic white women.
- Author
-
Becker TM, Lee F, Daling JR, Nahmias AJ, Becker, T M, Lee, F, Daling, J R, and Nahmias, A J
- Published
- 1996
- Full Text
- View/download PDF
22. Diet and genital warts: a case-control study.
- Author
-
Bairati I, Sherman KJ, McKnight B, Habel LA, Van den Eeden SK, Stergachis A, Daling JR, Bairati, I, Sherman, K J, McKnight, B, Habel, L A, Van den Eeden, S K, Stergachis, A, and Daling, J R
- Published
- 1994
23. Multiple primary tumours in women with vulvar neoplasms: a case-control study.
- Author
-
Sherman, KJ, Daling, JR, Chu, J, McKnight, B, and Weiss, NS
- Published
- 1988
- Full Text
- View/download PDF
24. Re: 'Studies with low response proportions may be less biased than studies with high response proportions'.
- Author
-
Voigt LF, Boudreau DM, Weiss NS, Malone KE, Li CI, Daling JR, Stang A, and Jöckel K
- Published
- 2005
- Full Text
- View/download PDF
25. Prior condom use and the risk of tubal pregnancy.
- Author
-
Li D, Daling JR, Stergachis AS, Chu J, and Weiss NS
- Abstract
The relationship between prior condom use and tubal pregnancy was assessed in a population-based case-control study at Group Health Cooperative of Puget Sound during 1981-86. We interviewed 227 women with a tubal pregnancy who had no clinical indication of infertility and no history of sterilization and 674 similarly defined controls who were matched to the cases on age and county of residence. A history of condom use for more than one year was associated with a decreased risk of subsequent tubal pregnancy (RR = 0.74, 95% CI = 0.44, 1.26) adjusted for the effects of age, current use of contraceptive methods, educational level, and age at first intercourse. The effect was more pronounced when condoms had been used during five-year periods with more than one partner (RR = 0.38, 95% CI = 0.15, 1.0) than during five-year periods with one partner (RR = 0.89, 95% CI = 0.45, 1.76). Condom use for less than one year was unrelated to risk of ectopic pregnancy. Since the use of condoms offers protection against sexually transmitted diseases, one or more of which are likely to be causally related to tubal pregnancy, the observed negative association plausibly represents a protective influence of long-term condom use on the occurrence of tubal pregnancy. [ABSTRACT FROM AUTHOR] more...
- Published
- 1990
- Full Text
- View/download PDF
26. Risk of anogenital cancer in women with CIN.
- Author
-
Daling JR
- Published
- 2007
- Full Text
- View/download PDF
27. Breast cancer and hormonal contraceptives: further results: Collaborative group on hormonal factors in breast cancer
- Author
-
Calle, EE, Heath, CW, Jr, Miracle-McMahill, HL, Coates, RJ, Liff, JM, Franceschi, S, Talamini, R, Chantarakul, N, Koetsawang, S, Rachawat, D, Morabia, A, Schuman, L, Stewart, W, Szklo, M, Bain, C, Schofield, F, Siskind, V, Band, P, Coldman, AJ, Gallagher, RP, Hislop, TG, Yang, P, Duffy, SW, Kolonel, LM, Nomura, AMY, Oberle, MW, Ory, HW, Peterson, HB, Wilson, HG, Wingo, PA, Ebeling, K, Kunde, D, Nishan, P, Colditz, G, Martin, N, Pardthaisong, T, Silpisornkosol, S, Theetranont, C, Boosiri, B, Chutivongse, S, Jimakorn, P, Virutamasen, P, Wongsrichanalai, C, McMichael, AJ, Rohan, T, Ewertz, M, Paul, C, Skegg, DCG, Spears, GFS, Boyle, P, Evstifeeva, T, Daling, JR, Malone, K, Noonan, EA, Stanford, JL, Thomas, DB, Weiss, NS, White, E, Andrieu, N, Brêmond, A, Clavel, F, Gairard, B, Lansac, J, Piana, L, Renaud, R, Fine, SRP, Cuevas, HR, Ontiveros, P, Palet, A, Salazar, SB, Aristizabel, N, Cuadros, A, Bachelot, A, Leê, MG, Deacon, J, Peto, J, Taylor, CN, Alfandary, E, Modan, B, Ron, E, Friedman, GD, Hiatt, RA, Bishop, T, Kosmelj, K., Primic-Zakelj, M, Ravnihar, B, Stare, J, Beeson, WL, Fraser, G, Allen, DS, Bulbrook, RD, Cuzick, J, Fentiman, IS, Hayward, JL, Wang, DY, Hanson, RL, Leske, MC, Mahoney, MC, Nasca, PC, Varma, AO, Weinstein, AL, Moller, TR, Olsson, H, Ranstam, J, Goldbohm, RA, van den Brandt, PA, Apelo, RA, Baens, J, de la Cruz, JR, Javier, B, Lacaya, LB, Ngelangel, CA, La Vecchia, C, Negri, E, Marbuni, E, Ferraroni, M, Gerber, M, Richardson, S, Segala, C, Gatei, D, Kenya, P, Kungu, A, Mati, JG, Brinton, LA, Hoover, R, Schairer, C, Spirtas, R, Lee, HP, Rookus, MA, van Leeuwen, FE, Schoenberg, JA, Gammon, MD, Clarke, EA, Jones, L, McPherson, K, Neil, A, Vessey, M, Yeates, D., Beral, V, Bull, D, Crossley, B, Hermon, C, Jones, S, Key, T, Reeves, Clewis G, Smith, P, Collins, R, Doll, R, Peto, R, Hannaford, P, Kay, C, Rosero-Bixby, L, Yuan, J-M, Wei, HY, Yun, T, Zhiheng, C, Berry, G, Booth, J Cooper, Jelihovsky, T, Maclennan, R, Shearman, R, Wang, Q-S, Baines, CJ, Miller, AB, Wall, C, Lund, E, Stalsberg, H, Dabancens, A, Martinez, L, Molina, R, Salas, O, Alexander, FE, Hulka, BS, Chilvers, CED, Bernstein, L, Haile, RW, Paganini-Hill, A, Pike, MC, Ross, RK, Ursin, G, Yu, MC, Adami, HO, Bergstrom, R, Longnecker, MP, Farley, TMN, Holck, S, and Meirik, O more...
- Published
- 1996
- Full Text
- View/download PDF
28. Oral contraceptives and the risk of breast cancer.
- Author
-
Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Weiss LK, Wingo PA, Burkman RT, Berlin JA, Simon MS, and Spirtas R
- Published
- 2002
29. The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results.
- Author
-
Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK, Liff JM, Wingo PA, Burkman RT, Folger SG, Berlin JA, Deapen DM, Ursin G, Coates RJ, Simon MS, and Press MF more...
- Abstract
Purpose: This paper presents methods and operational results of a population-based case-control study examining the effects of oral contraceptive use on breast cancer risk among white and black women aged 35-64 years in five U.S. locations.Methods: Cases were women newly diagnosed with breast cancer during July 1994 through April 1998. Controls were identified through random digit dialing (RDD) using unclustered sampling with automated elimination of nonworking numbers. Sampling was density-based, with oversampling of black women. In-person interviews were conducted from August 1994 through December 1998. Blood samples were obtained from subsets of cases and controls, and tissue samples were obtained from subsets of cases. A computerized system tracked subjects through study activities. Special attention was devoted to minimizing exposure misclassification, because any exposure-disease associations were expected to be small.Results: An estimated 82% of households were screened successfully through RDD. Interviews were completed for 4575 cases (2953 whites; 1622 blacks) and 4682 controls (3021 whites; 1661 blacks). Interview response rates for cases and controls were 76.5% and 78.6%, respectively, with lower rates for black women and older women.Conclusions: The methodologic details of this large collaboration may assist researchers conducting similar investigations. [ABSTRACT FROM AUTHOR] more...- Published
- 2002
- Full Text
- View/download PDF
30. Risk of ovulatory infertility in relation to body weight
- Author
-
Green, BB, Weiss, NS, and Daling, JR
- Published
- 1989
- Full Text
- View/download PDF
31. BRCA1 mutations in a population-based sample of young women with breast cancer.
- Author
-
Langston AA, Malone KE, Thompson JD, Daling JR, and Ostrander EA
- Published
- 1996
32. Risk of squamous cell skin cancer after organ transplant associated with antibodies to cutaneous papillomaviruses, polyomaviruses, and TMC6/8 (EVER1/2) variants.
- Author
-
Madeleine MM, Carter JJ, Johnson LG, Wipf GC, Davis C, Berg D, Nelson K, Daling JR, Schwartz SM, and Galloway DA
- Subjects
- Carcinoma, Squamous Cell epidemiology, Case-Control Studies, Genotype, Humans, Odds Ratio, Papillomaviridae classification, Risk, Skin Neoplasms epidemiology, Carcinoma, Squamous Cell etiology, Genetic Variation, Organ Transplantation adverse effects, Papillomaviridae genetics, Papillomavirus Infections complications, Skin Neoplasms etiology
- Abstract
Squamous cell skin cancer (SCSC) disproportionately affects organ transplant recipients, and may be related to increased viral replication in the setting of immune suppression. We conducted a nested case-control study among transplant recipients to determine whether SCSC is associated with antibodies to cutaneous human papillomaviruses (HPV), to genes associated with a rare genetic susceptibility to HPV (TMC6/TMC8), or to human polyomaviruses (HPyV). Cases (n = 149) had histologically confirmed SCSC, and controls (n = 290) were individually matched to cases on time since transplant, type of transplant, gender, and race. All subjects had serum drawn immediately prior to transplant surgery. Antibodies to 25 cutaneous HPVs and six HPyVs were assayed by detection of binding to virus-like particles, and 11 TMC6/8 variants were genotyped. After correction for multiple comparisons, only antibodies to HPV37 were associated with SCSC (OR 2.0, 95% CI 1.2-3.4). Common genetic variants of TMC6/8 were not associated with SCSC, but three variants in TMC8 (rs12452890, rs412611, and rs7208422) were associated with greater seropositivity for species 2 betapapillomaviruses among controls. This study suggests that some betaHPVs, but not polyomaviruses, may play a role in the excess risk of SCSC among transplant recipients., (© 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.) more...
- Published
- 2014
- Full Text
- View/download PDF
33. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.
- Author
-
Li CI, Daling JR, Haugen KL, Tang MT, Porter PL, and Malone KE
- Subjects
- Aged, Breast Neoplasms metabolism, Breast Neoplasms pathology, Carcinoma, Ductal, Breast metabolism, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular metabolism, Carcinoma, Lobular pathology, Case-Control Studies, Estrogen Replacement Therapy adverse effects, Estrogens therapeutic use, Female, Humans, Menopause, Middle Aged, Progestins therapeutic use, Receptors, Estrogen metabolism, Risk Assessment, Breast Neoplasms chemically induced, Carcinoma, Ductal, Breast chemically induced, Carcinoma, Lobular chemically induced, Hormone Replacement Therapy adverse effects
- Abstract
The Women's Health Initiative (WHI) randomized trials found that use of combined estrogen and progestin menopausal hormone therapy (CHT) increases breast cancer risk, but use of unopposed estrogen hormone therapy (EHT) does not. However, several questions regarding the impact of hormone use on risk of different types of breast cancer and what thresholds of use confer elevations in risk remain. We conducted a population-based case-control study among women 55-74 years of age to assess the association between menopausal hormone use and risk of invasive ductal and invasive lobular breast carcinomas. Associations were evaluated using polytomous logistic regression and analyses included 880 ductal cases, 1,027 lobular cases, and 856 controls. Current EHT and CHT use were associated with 1.6-fold [95 % confidence interval (CI): 1.1-2.2] and 2.3-fold (95 % CI: 1.7-3.2) increased risks of lobular breast cancer, respectively, but neither was associated with risk of ductal cancer. Lobular cancer risk was increased after 9 years of EHT use, but after only 3 years of CHT use. Evidence across more than a dozen studies indicates that lobular carcinoma is the type of breast cancer most strongly influenced by menopausal hormones. Here, we characterize what thresholds of duration of use of both EHT and CHT that confer elevations in risk. Despite the rapid decline in hormone therapy use the WHI results were published, study of the hazards associated with these medications remains relevant given the estimated 38 million hormone therapy prescriptions that are still filled in the United States annually. more...
- Published
- 2014
- Full Text
- View/download PDF
34. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.
- Author
-
Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, and Li CI
- Subjects
- Adult, Age Factors, Breast Neoplasms chemically induced, Case-Control Studies, Female, Follow-Up Studies, Humans, Odds Ratio, Prognosis, Receptors, Estrogen metabolism, Risk Factors, Triple Negative Breast Neoplasms chemically induced, United States epidemiology, Young Adult, Breast Neoplasms classification, Breast Neoplasms epidemiology, Contraceptives, Oral adverse effects, Triple Negative Breast Neoplasms epidemiology
- Abstract
Background: Evidence suggests that recent oral contraceptive (OC) use is associated with a small increased breast cancer risk; yet risks associated with contemporary OC preparations and by molecular subtype are not well characterized., Methods: We conducted a population-based case-control study of invasive breast cancer among women ages 20 to 44 residing in the Seattle-Puget Sound area from 2004 to 2010 (985 cases and 882 controls). We collected information on contraceptive use and participant characteristics via an in-person interview. Multivariable-adjusted logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI)., Results: Lifetime duration of OC use for ≥ 15 years was associated with an increased breast cancer risk (OR, 1.5; 95% CI, 1.1-2.2). Current OC use (within 1 year of reference date) for ≥ 5 years was associated with an increased risk (OR, 1.6; 95% CI, 1.1-2.5) and there were no statistically significant differences in risk by OC preparation. Risk magnitudes were generally greater among women ages 20 to 39, and for estrogen receptor-negative (ER(-)) and triple-negative breast cancer (current use for ≥ 5 years among ages 20-39: ER(-) OR, 3.5; 95% CI, 1.3-9.0; triple-negative OR, 3.7; 95% CI, 1.2-11.8), although differences between groups were not statistically significant., Conclusions: Long-term use of contemporary OCs and current use for ≥ 5 years was associated with an increased breast cancer risk among women ages 20 to 44. Risk may be greater among younger women and for ER(-) and triple-negative breast cancer, but these findings require confirmation., Impact: Continued surveillance and pooled analyses of OC use and breast cancer risk by molecular subtype are needed as OC preparations evolve., (©2014 AACR.) more...
- Published
- 2014
- Full Text
- View/download PDF
35. Cohort profile: the skin cancer after organ transplant study.
- Author
-
Madeleine MM, Johnson LG, Daling JR, Schwartz SM, Carter JJ, Berg D, Nelson K, Davis CL, and Galloway DA
- Subjects
- Adolescent, Adult, Aged, Carcinoma, Squamous Cell immunology, Case-Control Studies, Cohort Studies, Female, Humans, Male, Middle Aged, Papillomavirus Infections immunology, Prospective Studies, Retrospective Studies, Skin Neoplasms immunology, Young Adult, Carcinoma, Squamous Cell epidemiology, Graft Rejection prevention & control, Heart Transplantation, Immunocompromised Host, Immunosuppressive Agents adverse effects, Kidney Transplantation, Papillomavirus Infections epidemiology, Skin Neoplasms epidemiology
- Abstract
The Skin Cancer after Organ Transplant (SCOT) study was designed to investigate the link between genus beta human papillomavirus (HPV) and squamous cell skin cancer (SCSC). We focused on a population receiving immunosuppressive therapy for extended periods, transplant patients, as they are at extremely high risk for developing SCSC. Two complementary projects were conducted in the Seattle area: (i) a retrospective cohort with interview data from 2004 recipients of renal or cardiac transplants between 1995 and 2010 and (ii) a prospective cohort with interview data from 328 people on the transplant waiting lists between 2009 and 2011. Within the retrospective cohort, we developed a nested case-control study (172 cases and 337 control subjects) to assess risk of SCSC associated with markers of HPV in SCSC tumour tissue and eyebrow hair bulb DNA (HPV genotypes) and blood (HPV antibodies). In the prospective cohort, 135 participants had a 1-year post-transplant visit and 71 completed a 2-year post-transplant visit. In both arms of the cohort, we collected samples to assess markers of HPV infection such as acquisition of new types, proportion positive for each type, persistence of types at consecutive visits and number of HPV types detected. In the prospective cohort, we will also examine these HPV markers in relation to levels of cell-mediated immunity. The goal of the SCOT study is to use the data we collected to gain a more complete understanding of the role of immune suppression in HPV kinetics and of genus beta HPV types in SCSC. For more information, please contact the principal investigator through the study website: http://www.fhcrc.org/science/phs/cerc/The_SCOT_Study.html. more...
- Published
- 2013
- Full Text
- View/download PDF
36. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years.
- Author
-
Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, and Malone KE
- Subjects
- Aged, Antihypertensive Agents adverse effects, Breast Neoplasms etiology, Carcinoma, Ductal, Breast etiology, Carcinoma, Lobular etiology, Female, Humans, Hypertension complications, Incidence, Middle Aged, Odds Ratio, Retrospective Studies, Risk Factors, Survival Rate trends, Time Factors, Washington epidemiology, Antihypertensive Agents therapeutic use, Breast Neoplasms epidemiology, Carcinoma, Ductal, Breast epidemiology, Carcinoma, Lobular epidemiology, Hypertension drug therapy, Postmenopause, Risk Assessment methods
- Abstract
Importance: Antihypertensive agents are the most commonly prescribed class of medications in the United States. Evidence regarding the relationship between different types of antihypertensives and breast cancer risk is sparse and inconsistent, and prior studies have lacked the capacity to assess impacts of long-term use., Objective: To evaluate associations between use of various classes of antihypertensive medications and risks of invasive ductal and invasive lobular breast cancers among postmenopausal women., Design, Setting, and Participants: Population-based case-control study in the 3-county Seattle-Puget Sound metropolitan area. Participants were women aged 55 to 74 years, 880 of them with invasive ductal breast cancer, 1027 with invasive lobular breast cancer, and 856 with no cancer serving as controls., Exposures: Recency and duration of use of antihypertensive medications., Main Outcomes and Measures: Risks of invasive ductal and invasive lobular breast cancers., Results: Current use of calcium-channel blockers for 10 or more years was associated with higher risks of ductal breast cancer (odds ratio [OR], 2.4; 95% CI, 1.2-4.9) (P= .04 for trend) and lobular breast cancer (OR, 2.6; 95% CI, 1.3-5.3) (P= .01 for trend). This relationship did not vary appreciably by type of calcium-channel blocker used (short-acting vs long-acting, dihydropyridines vs non-dihydropyridines). In contrast, use of diuretics, β-blockers, and angiotensin II antagonists were not associated with risk., Conclusions and Relevance: While some studies have suggested a positive association between calcium-channel blocker use and breast cancer risk, this is the first study to observe that long-term current use of calcium-channel blockers in particular are associated with breast cancer risk. Additional research is needed to confirm this finding and to evaluate potential underlying biological mechanisms. more...
- Published
- 2013
- Full Text
- View/download PDF
37. Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age.
- Author
-
McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, and Li CI
- Subjects
- Aged, Breast Neoplasms chemically induced, Breast Neoplasms pathology, Carcinoma, Ductal, Breast chemically induced, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular chemically induced, Carcinoma, Lobular pathology, Case-Control Studies, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Middle Aged, Risk Factors, Washington epidemiology, Breast Neoplasms epidemiology, Carcinoma, Ductal, Breast epidemiology, Carcinoma, Lobular epidemiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage
- Abstract
Background: Mechanistic studies largely support the chemopreventive potential of statins. However, results of epidemiologic studies investigating statin use and breast cancer risk have been inconsistent and lacked the ability to evaluate long-term statin use., Methods: We used data from a population-based case-control study of breast cancer conducted in the Seattle-Puget Sound region to investigate the relationship between long-term statin use and breast cancer risk. Nine hundred sixteen invasive ductal carcinoma (IDC) and 1,068 invasive lobular carcinoma (ILC) cases in patients 55 to 74 years of age diagnosed between 2000 and 2008 were compared with 902 control women. All participants were interviewed in-person and data on hypercholesterolemia and all episodes of lipid-lowering medication use were collected through a structured questionnaire. We assessed the relationship between statin use and IDC and ILC risk using polytomous logistic regression., Results: Current users of statins for 10 years or longer had a 1.83-fold increased risk of IDC [95% confidence interval (CI): 1.14-2.93] and a 1.97-fold increased risk of ILC (95% CI: 1.25-3.12) compared with never users of statins. Among women diagnosed with hypercholesterolemia, current users of statins for 10 years or longer had more than double the risk of both IDC (OR: 2.04, 95% CI: 1.17-3.57) and ILC (OR: 2.43, 95% CI: 1.40-4.21) compared with never users., Conclusion: In this contemporary population-based case-control study, long-term use of statins was associated with increased risks of both IDC and ILC., Impact: Additional studies with similarly high frequencies of statin use for various durations are needed to confirm this novel finding., (©2013 AACR.) more...
- Published
- 2013
- Full Text
- View/download PDF
38. Nucleotide variation in IL-10 and IL-12 and their receptors and cervical and vulvar cancer risk: a hybrid case-parent triad and case-control study.
- Author
-
Hussain SK, Madeleine MM, Johnson LG, Du Q, Galloway DA, Daling JR, Malkki M, Petersdorf EW, and Schwartz SM
- Subjects
- Adult, Aged, Case-Control Studies, Female, Genetic Predisposition to Disease, Genotype, Humans, Interleukin-10 Receptor beta Subunit genetics, Interleukin-12 Subunit p35 genetics, Interleukin-12 Subunit p40 genetics, Middle Aged, Odds Ratio, Parents, Research Design, Risk Assessment, Risk Factors, Adenocarcinoma genetics, Carcinoma, Squamous Cell genetics, Interleukin-10 genetics, Interleukin-12 genetics, Nucleotides genetics, Polymorphism, Single Nucleotide, Receptors, Interleukin-10 genetics, Receptors, Interleukin-12 genetics, Uterine Cervical Neoplasms genetics, Vulvar Neoplasms genetics
- Abstract
Given the important role of cell mediated immunity in viral clearance and control of premalignant lesions, we hypothesize that variation in the IL-12/IL-10 cytokine and cytokine receptor genes may influence cervical and vulvar cancer risk. We evaluated 76 tagSNPs from seven candidate genes (IL-10, IL-12A, IL-12B, IL-10RA, IL-10RB, IL-12RB1, and IL12RB2) in case-parent sets (n=43 cervical squamous cell carcinoma (SCC), n=96 cervical adenocarcinoma, n=53 vulvar SCC), additional cases (n=356 cervical SCC, n=406 cervical adenocarcinoma, and n=473 vulvar SCC) and population based controls (1,111). We calculated log-additive odds ratios (ORs) and 95% confidence intervals (CIs) for the association between tagSNP and cancer risk using a pseudo-likelihood based method which combined genotype information on cases, parents, and population controls. After correction for multiple comparisons, we identified several statistically significant SNP associations. Cervical SCC risk was associated with the minor alleles of the IL10RA rs9610 3' UTR SNP (OR=1.76, 95% CI=1.15-2.68) and two synonymous IL12RB2 SNPs (rs4297265, OR=0.46, 95% CI=0.26-0.82; rs2229546, OR=0.43, 95% CI=0.21-0.87). Cervical adenocarcinoma risk was associated with the minor alleles of the IL10RA rs4252314 intronic SNP (OR=2.23, 95% CI=1.26-3.96) and IL12RB1 rs11575934 non-synonymous SNP (OR=1.51, 95% CI=1.12-2.05). Finally, the minor allele of the IL12B rs3181224 3' UTR SNP was associated with a reduced risk of vulvar SCC (OR=0.30, 95% CI=0.12-0.74). These results raise the possibility that a shift in the balance of the immune response due to genetic variants in key cytokine genes could influence the development of cervical and vulvar cancer., (Copyright © 2012 UICC.) more...
- Published
- 2013
- Full Text
- View/download PDF
39. Use of antihypertensive medications and breast cancer risk.
- Author
-
Saltzman BS, Weiss NS, Sieh W, Fitzpatrick AL, McTiernan A, Daling JR, and Li CI
- Subjects
- Aged, Aged, 80 and over, Antihypertensive Agents adverse effects, Breast Neoplasms chemically induced, Cohort Studies, Female, Humans, Proportional Hazards Models, Prospective Studies, Risk Factors, United States epidemiology, Antihypertensive Agents administration & dosage, Breast Neoplasms epidemiology
- Abstract
Purpose: Use of specific antihypertensive medications (AHTs) has been hypothesized to increase breast cancer risk, but results across published studies are inconsistent., Methods: We re-evaluated the relationship between AHT use and breast cancer risk in a prospective cohort of 3,201 women ≥65 years of age at recruitment now with more than double the length of follow-up (12 vs. 5 years) and substantially more breast cancer diagnoses (188 compared with 75 cases). We estimated the association between AHT use overall as well as use of specific formulations (based on data collected annually) and breast cancer risk using multivariate-adjusted Cox regression., Results: Compared with women who reported no use of AHTs, women who had used calcium channel blockers (CCB) within the past two years had a 1.6-fold increased risk of breast cancer (95 % confidence interval (CI): 1.0-2.5), and in particular, recent users of immediate-release CCBs had a 2.4-fold increased risk (95 % CI: 1.3-4.5). Neither ever nor recent use of any other type of AHT was associated with breast cancer risk., Conclusions: While the observed association between immediate-release CCBs and breast cancer risk is based on a small sample size and needs to be interpreted cautiously, this result is consistent with others in the literature. However, given declines in use of these preparations in favor of sustained-release CCBs, which was not related to risk, the potential clinical and public health impact of this association is limited. This study also adds to the evidence that other commonly used AHTs are not strongly related to breast cancer risk. more...
- Published
- 2013
- Full Text
- View/download PDF
40. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.
- Author
-
Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, and Malone KE
- Subjects
- Adult, Breast Feeding, Breast Neoplasms epidemiology, Case-Control Studies, Female, Humans, Logistic Models, Menarche, Oregon, Parity, Pregnancy, Young Adult, Breast Neoplasms etiology, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Reproductive History
- Abstract
Aspects of reproductive history are among the most well-established breast cancer risk factors. However, relatively little is known about how they influence risk of different molecular subtypes of breast cancer, particularly among younger women. Using data from a population-based case-control study of women 20-44 years of age, we assessed the relationships between various reproductive factors and risk of estrogen receptor positive (ER+), triple-negative, and HER2-overexpressing breast cancers. Detailed reproductive histories were obtained through structured interviewer administered in-person questionnaires. Reproductive histories among control women (n = 941) were compared to those of ER+ cases (n = 781), triple-negative cases (n = 180), and HER2-overexpressing cases (n = 60) using polytomous logistic regression. Age at menarche, parity, and number of full-term pregnancies were similarly associated with risk of all three breast cancer subtypes. In contrast, age at first live birth, the interval between age at menarche and age at first birth, and breastfeeding were inversely associated with risk of triple-negative breast cancer (P values for trend 0.002, 0.006 and 0.018, respectively), but were not associated with risk of ER+ or HER2-overexpressing cancers. A strong inverse association between breastfeeding and risk of triple-negative breast cancer has now been consistently observed across numerous studies, and at present it is the most well-established protective factor for this aggressive and lethal form of breast cancer. Further studies clarifying the biological mechanisms underlying this relationship and confirming our results with respect to age at first birth and the interval between age at menarche and age at first birth are needed. more...
- Published
- 2013
- Full Text
- View/download PDF
41. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
- Author
-
Saltzman BS, Malone KE, McDougall JA, Daling JR, and Li CI
- Subjects
- Adult, Aged, Biomarkers, Tumor, Breast Neoplasms metabolism, Breast Neoplasms pathology, Breast Neoplasms therapy, Case-Control Studies, Female, Humans, Middle Aged, Neoplasms, Second Primary metabolism, Neoplasms, Second Primary pathology, Neoplasms, Second Primary therapy, Risk Factors, SEER Program, Washington, Young Adult, Breast Neoplasms epidemiology, Neoplasms, Second Primary epidemiology, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism
- Abstract
Breast cancer survivors have a 60 % higher risk of developing a second primary asynchronous contralateral breast cancer (CBC) compared to women's risk of developing a first primary breast cancer (FBC). However, little is known about how expression of tumor markers in first breast cancers influences CBC risk. We conducted a population-based nested case-control study among women 20-74 years of age diagnosed with a first breast cancer between 1996 and 2008 in western Washington State to evaluate the association between their tumor's estrogen receptor (ER), progesterone receptor (PR) and HER2-neu (HER2) expression, and risk of CBC. The study included 482 cases diagnosed with both a FBC and a CBC and 1,506 control women diagnosed only once with breast cancer identified through our local Surveillance, Epidemiology and End Results (SEER) cancer registry. Compared to the women whose FBC was ER+/PR+, those with ER-/PR- first tumors had a 1.6-fold (95 % confidence interval (CI): 1.2-2.3) increased risk of developing a CBC. When evaluated by joint ER/PR/HER2 status, compared to women with ER+/HER2- first cancers, those with HER2-overexpressing (ER-/HER2+) and triple-negative disease (ER-/PR-/HER2-) had 2.0-fold (95 % CI: 1.1-3.8) and 1.4-fold (95 % CI: 0.9-2.3) elevated risks of developing CBC, respectively. Beyond the known higher risks of mortality among patients diagnosed with more aggressive BC subtypes, here, we observe that they may also have increased risks of developing CBC. more...
- Published
- 2012
- Full Text
- View/download PDF
42. Estrogen-related genes and their contribution to racial differences in breast cancer risk.
- Author
-
Reding KW, Chen C, Lowe K, Doody DR, Carlson CS, Chen CT, Houck J, Weiss LK, Marchbanks PA, Bernstein L, Spirtas R, McDonald JA, Strom BL, Burkman RT, Simon MS, Liff JM, Daling JR, and Malone KE
- Subjects
- Adult, Aged, Black People, Breast Neoplasms ethnology, Case-Control Studies, Female, Gene-Environment Interaction, Genetic Predisposition to Disease, Genetic Variation, Humans, Middle Aged, Polymorphism, Single Nucleotide, Risk Factors, White People, Breast Neoplasms genetics, Breast Neoplasms metabolism, Estrogens genetics, Estrogens metabolism
- Abstract
Racial differences in breast cancer risk, including the risks of hormone receptor subtypes of breast cancer, have been previously reported. We evaluated whether variation in genes related to estrogen metabolism (COMT, CYP1A1, CYP1B1, CYP17A1, CYP19A1, ESR1, GSTM1, GSTP1, GSTT1, HSD17B1, SULT1A1, and UGT1A1) contributes to breast cancer risk and/or racial differences in risk within the CARE study, a multi-centered, population-based case-control study of breast cancer. Genetic variation was assessed as single nucleotide polymorphisms (SNPs), haplotypes, and SNP-hormone therapy (HT) interactions within a subset of 1,644 cases and 1,451 controls, including 949 Black women (493 cases and 456 controls), sampled from the CARE study population. No appreciable associations with breast cancer risk were detected for single SNPs or haplotypes in women overall. We detected SNP-HT interactions in women overall within CYP1B1 (rs1800440; p (het) = 0.003) and within CYP17A1 (rs743572; p (het) = 0.009) in which never users of HT were at a decreased risk of breast cancer, while ever users were at a non-significant increased risk. When investigated among racial groups, we detected evidence of an SNP-HT interaction with CYP1B1 in White women (p value = 0.02) and with CYP17A1 in Black women (p value = 0.04). This analysis suggests that HT use may modify the effect of variation in estrogen-related genes on breast cancer risk, which may affect Black and White women to a different extent. more...
- Published
- 2012
- Full Text
- View/download PDF
43. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age.
- Author
-
Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, and Malone KE
- Subjects
- Adult, Case-Control Studies, Female, Humans, Risk Factors, Young Adult, Breast Neoplasms chemically induced, Breast Neoplasms epidemiology, Contraceptive Agents, Female adverse effects, Medroxyprogesterone Acetate adverse effects
- Abstract
Depo-medroxyprogesterone acetate (DMPA) is an injectable contraceptive that contains the same progestin as the menopausal hormone therapy regimen found to increase breast cancer risk among postmenopausal women in the Women's Health Initiative clinical trial. However, few studies have evaluated the relationship between DMPA use and breast cancer risk. Here, we conducted a population-based case-control study among 1,028 women ages 20 to 44 years to assess the association between DMPA use and breast cancer risk. Detailed information on DMPA use and other relevant covariates was obtained through structured interviewer-administered in-person questionnaires, and unconditional logistic regression was used to evaluate associations between various aspects of DMPA use and breast cancer risk. We found that recent DMPA use for 12 months or longer was associated with a 2.2-fold [95% confidence interval (CI), 1.2-4.2] increased risk of invasive breast cancer. This risk did not vary appreciably by tumor stage, size, hormone receptor expression, or histologic subtype. Although breast cancer is rare among young women and the elevated risk of breast cancer associated with DMPA appears to dissipate after discontinuation of use, our findings emphasize the importance of identifying the potential risks associated with specific forms of contraceptives given the number of available alternatives. more...
- Published
- 2012
- Full Text
- View/download PDF
44. Oral contraceptive formulation and risk of breast cancer.
- Author
-
Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, McDonald JA, Daling JR, Bernstein L, Malone KE, Wingo PA, Simon MS, Norman SA, Strom BL, Ursin G, Weiss LK, Burkman RT, and Spirtas R more...
- Subjects
- Adult, Case-Control Studies, Female, Humans, Interviews as Topic, Middle Aged, Risk, Surveys and Questionnaires, Breast Neoplasms chemically induced, Contraceptives, Oral adverse effects, Contraceptives, Oral, Hormonal adverse effects
- Abstract
Background: While evidence on the association between oral contraceptive (OC) use and breast cancer generally suggests little or no increased risk, the question of whether breast cancer risk varies by OC formulation remains controversial. Few studies have examined this issue because large samples and extensive OC histories are required., Study Design: We used data from a multicenter, population-based, case-control investigation. Women aged 35-64 years were interviewed. To explore the association between OC formulation and breast cancer risk, we used conditional logistic regression to derive adjusted odds ratios, and we used likelihood ratio tests for heterogeneity to assess whether breast cancer risk varied by OC formulation. Key OC exposure variables were ever use, current or former use, duration of use and time since last use. To strengthen inferences about specific formulations, we restricted most analyses to the 2282 women with breast cancer and the 2424 women without breast cancer who reported no OC use or exclusive use of one OC., Results: Thirty-eight formulations were reported by the 2674 women who used one OC; most OC formulations were used by only a few women. We conducted multivariable analyses on the 10 formulations that were each used by at least 50 women and conducted supplemental analyses on selected formulations of interest based on recent research. Breast cancer risk did not vary significantly by OC formulation, and no formulation was associated with a significantly increased breast cancer risk., Conclusions: These results add to the small body of literature on the relationship between OC formulation and breast cancer. Our data are reassuring in that, among women 35-64 years of age, we found no evidence that specific OC formulations increase breast cancer risk., (Published by Elsevier Inc.) more...
- Published
- 2012
- Full Text
- View/download PDF
45. Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer.
- Author
-
Malone KE, Daling JR, Doody DR, O'Brien C, Resler A, Ostrander EA, and Porter PL
- Subjects
- Age Factors, Breast Neoplasms pathology, Cohort Studies, Family Health, Female, Genetic Predisposition to Disease, Genotype, Humans, Middle Aged, Risk Factors, SEER Program, United States epidemiology, Breast Neoplasms genetics, Breast Neoplasms mortality
- Abstract
Background: Inherited predisposition may be associated with distinctive breast cancer phenotypes and/or mortality. Past studies have had inconsistent results and little is known about the contributions of screening and treatment., Methods: Within a population-based cohort of 1,260 women diagnosed with invasive breast cancer before age 46, we assessed how family history of breast cancer relates to mortality and tumor characteristics. Analyses were repeated excluding BRCA1/BRCA2 carriers. Medical records were reviewed for treatment history and tumors were centrally reviewed and tested. Cox proportional hazard modeling was used to assess the risk of dying in relation to family history; logistic regression was used to assess the association of family history to tumor characteristics., Results: Compared with women with no family history, women with first-degree family history of breast cancer had a 40% reduction (95% CI: 0.5-0.8) in the risk of dying. Mortality in women with only a second-degree family history was similar to those with no family history. The risk of dying was further reduced in those with a greater number of affected relatives. These relationships did not seem to be attributable to differences in screening, detection method, or treatment. Tumors in women with a first-degree family history had generally more favorable prognostic profiles., Conclusion: Our findings suggest that breast cancer patients with a first-degree family history, compared with their counterparts without such a profile, may have a better prognosis., Impact: These findings support the need for future research directed at replicating these results and identifying factors underlying this possible relationship. more...
- Published
- 2011
- Full Text
- View/download PDF
46. Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer.
- Author
-
Reding KW, Doody DR, McTiernan A, Hsu L, Davis S, Daling JR, Porter PL, and Malone KE
- Subjects
- Age Factors, Aged, Cell Differentiation, Estrogens metabolism, Female, Humans, Mammography methods, Menopause, Middle Aged, Odds Ratio, Progestins metabolism, Risk, Breast Neoplasms chemically induced, Breast Neoplasms mortality, Hormone Replacement Therapy adverse effects, Hormones therapeutic use
- Abstract
Multiple past studies have reported a reduced risk of breast cancer-related mortality (BCM) in relation to pre-diagnostic use of hormone therapy (HT); however, the extent to which this reduction is due to heightened screening or tumor biology is unknown. Using a population-based cohort of 1,911 post-menopausal women diagnosed with invasive breast cancer at ages 45-79 from 1993 to 1999, we investigated the extent to which the reduced risk in BCM observed in relation to HT might be explained by screening patterns or tumor features. Estrogen-progestin therapy (EPT) use was associated with a decreased risk of BCM (after adjustment for age, study, mammography, stage, and treatment), but only among older women (ever use: ≥ 65 years: HR = 0.45 [95% CI 0.26-0.80]; <65 years: HR = 1.03 [95% CI 0.60-1.79]). Estrogen-alone therapy (ET) use was not associated with risk of BCM (ever use: ≥ 65 years: HR = 0.76 [95% CI 0.51-1.12]; <65 years: HR = 1.20 [95% CI 0.71-2.02]). HT users had a much greater frequency of mammography (P value <0.001). EPT use was associated with tumor characteristics related to improved prognosis in older women after adjustment for screening, including an inverse association with poorly differentiated tumors (OR = 0.57 [95% CI 0.38-0.85]) and an association with lobular tumors (OR = 1.68 [95% CI 1.07-2.65]). Beyond the influence of EPT use on screening uptake, these data indicate that the improved survival associated with pre-diagnostic EPT use may be due in part to the development of more favorable tumor characteristics. more...
- Published
- 2011
- Full Text
- View/download PDF
47. Relationship between menopausal symptoms and risk of postmenopausal breast cancer.
- Author
-
Huang Y, Malone KE, Cushing-Haugen KL, Daling JR, and Li CI
- Subjects
- Aged, Body Composition, Body Mass Index, Breast Neoplasms drug therapy, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Lobular drug therapy, Case-Control Studies, Cohort Studies, Female, Follow-Up Studies, Hot Flashes, Humans, Middle Aged, Prognosis, Risk Factors, Survival Rate, United States epidemiology, Breast Neoplasms epidemiology, Carcinoma, Ductal, Breast epidemiology, Carcinoma, Lobular epidemiology, Menopause, Postmenopause
- Abstract
Background: Prior studies indicate that women with menopausal symptoms have lower estrogen levels because they go through menopause as compared with women who do not experience them. Given the central role of hormones in the etiology of breast cancer, a link between menopausal symptoms and breast cancer is plausible. However, no prior studies have evaluated the association between menopausal symptoms and breast cancer risk., Methods: Utilizing data from a population-based case-control study we examined associations between menopausal symptoms and risks of different histologic types of breast cancer among postmenopausal women. We calculated multivariate adjusted odds ratios (OR) using polytomous logistic regression and evaluated several potential effect modifiers., Results: Women who ever experienced menopausal symptoms had lower risks of invasive ductal carcinoma [(IDC) OR = 0.5; 95% CI: 0.3-0.7], invasive lobular carcinoma (ILC, OR = 0.5; 95% CI: 0.3-0.8), and invasive ductal-lobular carcinoma (IDLC, OR = 0.7; 95% CI: 0.4-1.2), and these reductions in risk were independent of recency and timing of hormone therapy use, age at menopause, and body mass index. Increasing intensity of hot flushes among women who ever experienced hot flushes was also associated with decreasing risks of all three breast cancer subtypes (P values for trend all ≤ 0.017)., Conclusion: This is the first study to report that women who ever experienced menopausal symptoms have a substantially reduced risk of breast cancer, and that severity of hot flushes is also inversely associated with risk., Impact: If confirmed, these findings could enhance our understanding of breast cancer etiology and factors potentially relevant to prevention., (©2011 AACR.) more...
- Published
- 2011
- Full Text
- View/download PDF
48. Smoking during first pregnancy and breast cancer: a case-control study using Washington State registry data.
- Author
-
DeRoo LA, Cummings P, Daling JR, and Mueller BA
- Subjects
- Adult, Aged, Case-Control Studies, Cohort Studies, Female, Humans, Middle Aged, Registries statistics & numerical data, Risk, Washington epidemiology, Breast Neoplasms genetics, Pregnancy, Smoking adverse effects
- Abstract
Purpose: To examine whether smoking during first pregnancy, a time of potential vulnerability to tobacco mutagens, is associated with breast cancer., Methods: We conducted a nested case-control study within a cohort of Washington State residents with first deliveries during 1984-1999, identified in birth and fetal death records. Linkage to population-based cancer registry data identified 1,099 women in the cohort aged 65 years and younger diagnosed with breast cancer in 1985-2000. Controls (N=10,922) were matched by year and age of first delivery, race/ethnicity, and birth outcome. Maternal smoking and other variables characterizing the pregnancy were obtained from birth and fetal death records. Conditional logistic regression was used to analyze the data., Results: The adjusted risk ratio for breast cancer was 0.8, 95% confidence interval 0.7-0.9, among women who smoked during their pregnancy compared with similar women who did not smoke. When the sample was restricted to known state residents at the time of the matched case's diagnosis, there was no association (risk ratio 1.0; 0.8-1.1)., Conclusions: Our results do not suggest that cigarette smoking during first pregnancy increases the risk of breast cancer., (Published by Elsevier Inc.) more...
- Published
- 2011
- Full Text
- View/download PDF
49. Relationship between diabetes and risk of second primary contralateral breast cancer.
- Author
-
Li CI, Daling JR, Tang MT, and Malone KE
- Subjects
- Aged, Breast Neoplasms chemistry, Breast Neoplasms complications, Breast Neoplasms epidemiology, Case-Control Studies, Female, Humans, Middle Aged, Neoplasms, Second Primary complications, Odds Ratio, Receptors, Estrogen analysis, Risk Assessment, Risk Factors, SEER Program, Diabetes Mellitus, Type 2 complications, Neoplasms, Second Primary epidemiology
- Abstract
Breast cancer survivors have a substantially higher risk of developing a second primary contralateral breast cancer (CBC) compared to the risk of breast cancer among women in the general population. While data regarding the relationship between diabetes and breast cancer incidence are inconsistent, diabetes is more clearly linked to an elevated risk of all-cause mortality among breast cancer survivors. However, no prior studies have assessed its impact on CBC risk. We assessed the relationship between diabetes, and CBC risk in a population-based nested case-control study consisting of women 40-79 years of age diagnosed with a first primary ER-positive invasive breast cancer. It included 322 women who developed a second primary CBC and 616-matched control women diagnosed only with a first breast cancer. We used conditional logistic regression to quantify associations between diabetes and CBC risk. Compared to women without a history of diabetes, diabetics had a 2.2-fold [95% confidence interval (CI) 1.3-3.6] increased risk of CBC. This risk was more pronounced among women diagnosed with their first breast cancer before age 60 years (odds ratio, OR = 11.5, 95% CI 2.4-54.5), compared to those diagnosed at age 60 years or older (OR = 1.5, 95% CI 0.8-2.7, P for interaction = 0.011). Diabetics diagnosed with breast cancer appear to have an elevated risk of CBC. This is the first study to report this relationship, but if confirmed efforts to insure that diabetic breast cancer survivors are carefully screened for second breast cancers may be warranted. more...
- Published
- 2011
- Full Text
- View/download PDF
50. Infertility treatment use in relation to selected adverse birth outcomes.
- Author
-
Welmerink DB, Voigt LF, Daling JR, and Mueller BA
- Subjects
- Adult, Cohort Studies, Congenital Abnormalities epidemiology, Congenital Abnormalities etiology, Female, Fetal Death epidemiology, Humans, Infant, Newborn, Infant, Newborn, Diseases epidemiology, Infant, Newborn, Diseases etiology, Obstetric Labor Complications epidemiology, Obstetric Labor Complications etiology, Pregnancy, Reproductive Techniques, Assisted statistics & numerical data, Young Adult, Infertility therapy, Parturition physiology, Pregnancy Outcome epidemiology, Reproductive Techniques, Assisted adverse effects
- Abstract
Objective: To determine whether maternal infertility treatment is associated with adverse outcomes., Design: Population-based cohort study using linked birth certificate-hospital discharge data., Setting: Washington State., Patient(s): Live-born singleton infants conceived with infertility treatment between 2003 and 2006 (n = 2,182) and a random sample of live-born singleton infants conceived spontaneously, frequency matched by birth year (n = 10,989)., Intervention(s): None., Main Outcome Measure(s): Mantel-Haenszel adjusted relative risks (RRs) and 95% confidence intervals (CIs) were computed for low birth weight, delivery at <37 weeks, small for gestational age infants, any malformation, placenta previa, and placenta abruptio., Result(s): Women with infertility treatment were at increased risk of placental abnormalities, including placenta abruptio (RR, 1.6; 95% CI, 1.1-2.5) and placenta previa (RR, 3.0; 95% CI, 2.0-4.7). Their infants were more likely to be delivered at <37 weeks (RR, 1.7; 95% CI, 1.4-1.9) or weigh <2500 g (RR, 1.4; 95% CI, 1.1-1.7); however, they were not at increased risk of being small for gestational age. An increased risk of malformations was observed in infants born to older women with infertility treatment, but not to younger women., Conclusion(s): Women using infertility treatment are at increased risk for delivering preterm, placenta previa, and placenta abruptio. Studies with measurement of specific infertility treatments will help identify the mechanisms., (Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.) more...
- Published
- 2010
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.